Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
RESEARCH TOOLSreports
RPTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $7.45
Previous CloseN/A
Volume283.97K
Average Volume (3M)310.75K
Market Cap
$56.11M
Enterprise Value-$30.83M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Mar 04, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding42,510,708
10 Day Avg. Volume167,752
30 Day Avg. Volume310,755
Standard Deviation0.22
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.84
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.39
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$5.67Price Target Upside329.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Repare Therapeutics News
PremiumCompany Announcements
Repare Therapeutics Shifts Focus to Phase 1 Programs
---
Bulls Say, Bears Say
Bulls Say
Phase 1 Expansion ResultsRepare's phase 1 expansion results in endometrial and ovarian cancer represent strong signals of efficacy in heavily pre-treated, genomically-defined patients.
Proof Of Concept In Endometrial CancerAchieved proof of concept with lunresertib + camonsertib and sees opportunity for accelerated approval in endometrial cancer.
RP-3467 DevelopmentAnalyst maintains a Buy recommendation with optimism for RP-3467, which is based on promising preclinical data from both RPTX and IDYA.
Bears Say
Funding RisksFailure to drive support for RP-3467/RP-1664 could heighten funding risk for the company.
Pivotal Program ChallengesPivotal programs in gynecological cancers would be complicated and expensive due to the combination of two currently unapproved drugs.
PLK4 Target RisksPLK4 as a target is viewed as higher risk due to lack of confidence from prior attempts by competitors.
---
Ownership Overview
1.60% Insiders
0.20% Mutual Funds
66.74% Other Institutional Investors
26.54% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPTX FAQ
What was Repare Therapeutics Inc’s price range in the past 12 months?
Repare Therapeutics Inc lowest stock price was $1.10 and its highest was $7.45 in the past 12 months.
What is Repare Therapeutics Inc’s market cap?
Repare Therapeutics Inc’s market cap is $56.11M.
When is Repare Therapeutics Inc’s upcoming earnings report date?
Repare Therapeutics Inc’s upcoming earnings report date is Mar 04, 2025 which is in 10 days.
How were Repare Therapeutics Inc’s earnings last quarter?
Repare Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$0.871 by $0.061.
Is Repare Therapeutics Inc overvalued?
According to Wall Street analysts Repare Therapeutics Inc’s price is currently Undervalued.
Does Repare Therapeutics Inc pay dividends?
Repare Therapeutics Inc does not currently pay dividends.
What is Repare Therapeutics Inc’s EPS estimate?
Repare Therapeutics Inc’s EPS estimate is -0.79.
How many shares outstanding does Repare Therapeutics Inc have?
Repare Therapeutics Inc has 42,510,708 shares outstanding.
What happened to Repare Therapeutics Inc’s price movement after its last earnings report?
Repare Therapeutics Inc reported an EPS of -$0.81 in its last earnings report, beating expectations of -$0.871. Following the earnings report the stock price went down -3.324%.
Which hedge fund is a major shareholder of Repare Therapeutics Inc?
Currently, no hedge funds are holding shares in RPTX
---
Repare Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.67 (329.55% Upside)
$5.67 (329.55% Upside)
Hedge Fund Trend
Decreased
By 509.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.98%
12-Months-Change
Fundamentals
Return on Equity
-41.17%
Trailing 12-Months
Asset Growth
-27.94%
Trailing 12-Months
Company Description
Repare Therapeutics Inc
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
---
RPTX Stock 12 Month Forecast
Average Price Target
$5.67
▲(329.55% Upside)
Technical Analysis
Exelixis
―
Karyopharm Therapeutics
―
Minerva Neurosciences
―
Blueprint Medicines
―
Argenx Se
―
Best Analysts Covering RPTX
1 Year
1 Year Success Rate
1/18 ratings generated profit
1 Year Average Return
-46.53%
assigned a buy rating last month
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 5.56% of your transactions generating a profit, with an average return of -46.53% per trade.
---